E

Endo International PLC
LSE:0Y5F

Watchlist Manager
Endo International PLC
LSE:0Y5F
Watchlist
Price: 695.3 USD 2.4% Market Closed
Market Cap: 156B USD

Profitability Summary

Endo International PLC's profitability score is 55/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

55/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

55/100
Profitability
Score
55/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Endo International PLC

Revenue
2.3B USD
Cost of Revenue
-751.2m USD
Gross Profit
1.6B USD
Operating Expenses
-1.3B USD
Operating Income
259.8m USD
Other Expenses
-3.2B USD
Net Income
-2.9B USD

Margins Comparison
Endo International PLC Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
IE
Endo International PLC
LSE:0Y5F
163.5B USD
68%
11%
-126%
US
Eli Lilly and Co
NYSE:LLY
725.7B USD
82%
40%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
369.6B USD
68%
26%
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
84%
45%
35%
CH
Roche Holding AG
SIX:ROG
212.9B CHF
74%
33%
14%
CH
Novartis AG
SIX:NOVN
189.4B CHF
76%
33%
24%
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP
82%
24%
14%
US
Merck & Co Inc
NYSE:MRK
195.3B USD
78%
34%
27%
US
Pfizer Inc
NYSE:PFE
131.4B USD
75%
27%
13%
FR
Sanofi SA
PAR:SAN
109.7B EUR
70%
22%
14%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Endo International PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
IE
Endo International PLC
LSE:0Y5F
163.5B USD
70%
-51%
5%
6%
US
Eli Lilly and Co
NYSE:LLY
725.7B USD
78%
14%
38%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
369.6B USD
30%
12%
18%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
88%
27%
70%
30%
CH
Roche Holding AG
SIX:ROG
212.9B CHF
27%
9%
29%
20%
CH
Novartis AG
SIX:NOVN
189.4B CHF
33%
13%
26%
18%
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP
20%
7%
18%
14%
US
Merck & Co Inc
NYSE:MRK
195.3B USD
39%
16%
25%
19%
US
Pfizer Inc
NYSE:PFE
131.4B USD
9%
4%
10%
9%
FR
Sanofi SA
PAR:SAN
109.7B EUR
17%
10%
20%
16%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less